Trial
NCT01215578
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
—
Condition
Neuroendocrine Tumors
Intervention
Sutent
Why stopped
lack of recruitement
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-30